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INTRODUCTION
Ketamine is still wide-used anesthetic, especially in 
resource-poor countries. For instance, in Zambia the 
ketamine anesthesia seems to be used in every 
1second anesthetic management,  especially in 
district hospitals. This anesthetic has very 
complicated “course of life”: from general 
recognition till burning indignation. Despite of its 
ketamine takes sturdy stand for performing 
anesthesia in extremely critical conditions (e.g., 
hypovolaemic shock).
Ketamine – intravenous dissociative anesthetic 
agent developed by American pharmaceutist 
Stevens C. in Parke-Davis Lab (1962). In 1965 
professor Domino EF described ketamine as a 
2
potential psychedelic.  Dissociate anaesthesia is a 
trance-like cataleptic state characterized by 
profound analgesia, sedation, amnesia and 
immobilization, with retention of protective airway 
re f lexes ,  spontaneous  resp i ra t ions  and  
3cardiopulmonary stability.
PHARMACOLOGY
Ketamine – phencyclidine derivate and is classified 
as an N-methyl-D-aspartate (NMDA)-receptor 
antagonist. Ketamine contains a chiral center 
producing two optical isomers. The S (+)-
enantiomer (Ketanest S) would appear to offer some 
clinical advantages over the racemic mixture – R (-) 
because it's a more effective anesthetic and 
analgesic drug with a more rapid recovery and less 
4,5,6
psychotomimetic side-effects.  However more 
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Systemic name - 2-(2-chlorophenyl)-2-
methyamino-cyclohexan-1
Chemical formula – C H ClNO-HCl   13 16
Molecular weight – 274.19 
pH (ketamine hydrochloride) is 3.5-5.5 
(moderately acidic)
pKa – 7.5
Figure 1:  Chemical structure of ketamine
Water solutions of ketamine are stable at a room 




7Ønegligible protein binding – 12-35 % 
8
distribution half-life – 11-16 min 
 9
Øelimination half-life – 2-3 hrs




Øclearance – 12-17 ml/kg/min 
high lipid solubility (quick penetration into 
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Øextensively metabolized by hepatic 
microsomal cytochrome P-450 enzymes 
(N-demethylation). Its metabolite, water-
soluble, norketamine, has 1/3-1/5 potency 
and doesn't penetrate into central nervous 
system (CNS). 
ØOnly 2-3% as unchanged drug is excreted 
in the urine, approximately 90% is excreted 
the same way as metabolites. The rest of the 
drug by feces. 
Pharmacodynamics
Ketamine causes dissociation between the 
thalamocortical pathways and limbic systems 
10,11(hippocampus).  Ketamine blocks the open ion 
channel of the NMDA-receptors and inhibits 
glutamate activation, thereby reducing the 
excitatory effects of glutamate on neurons in the 
12CNS.  Anesthetic depresses the transmission of 
nerve impulses in the medial medullary reticular 
formation, blocking nociception from the spinal 
13
cord to brain pathways.  As well antagonizes 
muscarine and nicotinic acetylcholine receptors of 
14
the brain.  Perhaps it action at the nicotinic receptor 
15
is responsible for behavioral adverse effects.  
INFLUENCE ON
Central nervous system
During monoanesthesia by ketamine the cortical 
EEG are characterized by the appearance of β-
activity (4-7 Hz). That picture of generalized and 
hypersynchronized β-rhythm is characterized for the 
excitation of limbic brain structures (hippocampus). 
16It is known as limbic seizure.  If firstly administer 
benzodiazepines (e.g., diazepam, 0.1-0.2 mg/kg) 
then ketamine occur diazepam's tranquilization with 
the development of fast EEG-rhythm (15-25 Hz). 
Furthermore haemodynamics and respiration 
remain stable. 
Ketamine can activate epileptogenic foci in patients 
17
with known seizure disorders.  
Ketamine is generally causes the increase in cerebral 
blood flow (CBF), intracranial pressure (ICP) and 
cerebral oxygen consumption (CMRO ). In animal 2
study, the ketamine-induced increase in ICP was 
prevented by hyperventilation and diazepam pre-
18,19treatment.
Some animal studies have shown that ketamine may 
produce a marked neuroprotective effect mediated 
by antagonism of NMDA channels, therefore 
preventing calcium influx during states of 
20,21,22
neurocellular ishaemia.  However, the results of 
23
some animal experiments are contradictory.  
Cardiovascular system
Ketamine stimulates the cardiovascular system due 
to direct stimulation of the sympathetic nervous 
24system (central baroreflex inhibition).  Ketamine 
causes the sympathoneuronal release of 
25noradrenaline  and inhibits extraneuronal 
26noradrenaline uptake.  That's all explains the 
increase in arterial pressure (up to 15-20%), heart 
rate (up to 20%), pulmonary artery pressure (40-
47%) and cardiac output (up to 20%) usually seen on 
27
induction of anesthesia with ketamine.  These 
hemodynamic changes are not dose-related. 
Ketamine has intrinsic myocardial depressant 
effects which may become apparent only in the 
seriously ill patients with depleted catecholamine 
28
reserves.
Ketamine may compromise the balance between 
myocardial oxygen supply and demand in patients 
29with coronary ischemic disease.  In children with 
poor right ventricular reserve this drug seems to be 
30safe.  
Respiratory system
Ketamine has minimal effect on respiratory system. 
It is often recommended for induction of anesthesia 
in patients with asthma because of its ability to 
produce bronchodilation (effect on the central 
sympathetic system, direct relaxant affect on airway 
31
smooth muscles).  Concise apnoe is rarely seen 
which is associated with rapid or large dose of 
intravenous administration. Bronchorrhoea may 
also occur which can produce the laryngospasm in 
children (an antisialagogue usage is recommended). 
Gastrointestinal system
Hypersalivation. Don't affect liver function tests. 
Incidence of postoperative nausea and vomiting are 
minimal. 
Visual system
Ketamine increases intraocular pressure (IOP) for a 
 short time. In one study, Nagdeve NG et al, showed 
low-dose ketamine anesthesia (3 mg/kg IM) not 
altered the IOP compared induction dose (6 mg/kg 
32
IM) for pediatric surgery.  Nystagmus and eye 
movements may occur during surgical procedures. 
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Muscular system
Slightly enhanced skeletal muscle tone and 
movements are often occur. 
Immune system
Ketamine results in a significant reduction in 
leucocyte's activation during sepsis, while it also 
suppresses pro-inflammatory cytokine production 
in vitro.
Pregnancy
Ketamine crosses the placenta and concentration in 
the fetus is proportional to those in the mother. 
Pregnancy category – B. 
Psychoneurological effects
- Experimental antidepressant use: using 
subanesthetic doses of ketamine – 0.5 
mg/kg during 40-60 minutes helps in a 
33,34,35,36
treatment-resistant depression.  
NMDA is receptor for the neurotransmitter 
glutamate. The glutamate system has been 
implicated in depression recently, not only 
serotonin and norepinephrine. 
- Treatment of addiction: some studies were 
dedicated to the treatment for alcohol and 
37, 38heroin addiction.  
- Pharmacological model of schizophrenia: 
ketamine and other NMDA-antagonists 
(PCP, MK-80) are considered to be the best 
available pharmacological models of 
schizophrenia to date. Ketamine produce 
the negative symptoms (alogia, social 
wi thdrawal ) ,  pos i t ive  symptoms  
(delusions, hallucinations) and cognitive 
deficits of schizophrenia.
- “Club drug”: is also known as “special K” 
(www.clubdrugs.gov). It can be injected, 
snorted or smoked. In small doses ketamine 
can cause dream-like states and 
hallucinations (delusions). In high doses 
ketamine can cause amnesia, delirium, 
impaired motor function, high blood 
pressure and respiratory depression. In 
2003, 0.8 percent of young New Zealanders 
had tried ketamine, with 0.2% having used 
39within the previous year.  
INDICATIONS
1. Sedation: 
- in some minor surgical procedures: 
debridement, dressing changes, extraction, 
removal of tampon, EUA and so on.  
15- in the emergency department (ED)  
2. Anesthesia: 
- as induction agent in hypovolaemic and 
shocked patients (ASA IV class)
- in some specific pathology (see below)
- in the developing countries as a single 
general intravenous agent
3. Analgesia
- to relief an acute postoperative pain – 
i n h i b i t s  n o c i c e p t i v e  c e n t r a l  
40hypersensitization  and NMDA-receptor-
 41mediated ion currents  
- pre-emptive analgesia (subanaesthetic 
 42,43doses)
44- chronic cancer pain  
The usage in some specific conditions 
Cardiovascular surgery
Bartoc C. et al. have shown a significant anti-
inflammatory effect of low-dose ketamine (0.5 
mg/kg during induction of anesthesia) in cardiac 
surgical patients. It mitigated increases in IL-6 (pro-
inflammatory cytokine) and C-reactive protein, as 
well as increased in IL-10 (anti-inflammatory 
cytokine). Therefore these changes protect patients 
to some degree from vasodilatation in postoperative 
45 46, 47
period.  It's has been confirmed by other studies.  
Another study has been shown that ketamine is 
48preferable induction drug for pericardiectomy. 
Patients with endotoxemia (septic shock) 
Ketamine shows benefit effects (inhibited 
hypotension, metabolic acidosis and cytokines 
responses) in animal model with injected 
49, 50endotoxins.  
Patients with asthma 
Ketamine is a drug of choice as an induction agent at 
51, 52
asthmatic patients.  This anesthetic relaxes the 
b r o n c h i o l a r  m u s c u l a t u r e  ( d u e  t o  i t s  
sympathomimetic properties) and prevents the 
 53
bronchoconstriction induced by histamine , 
54
decreasing the risk of bronchospasm.  However, its 
effectiveness in asthma failed to demonstrate any 
55
benefits compared with standard therapy in the ED.  
Adjunct to regional anesthesia
There are some studies and case reports that 
ketamine can be used as an adjunct to neuroaxial 
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blocks by intrathecal or epidural route. An 
intrathecal dose of 1 mg ketamine combined with 
intrathecal morphine obtained effective pain relief 
 56in cancer patients.  Encouraging finding have been 
shown S (+)-ketamine strengthened the duration of 
57, 58 analgesia. But the Food and Drug Administration 
(FDA) has not approved ketamine for regional 
anesthesia. The probable cause - ketamine's 
preservative, chlorobutanol, has been demonstrated 
59neurotoxic effect during subarachnoid anesthesia.   
DOSAGE
- per os route of administration: 3-10 mg/kg. 
Onset of action in 10-12 min. Average 
60, 61
duration of action up to 25-40 min.  
- intramuscular route of administration: 4-5 
mg/kg for adult, 6-8 mg/kg for children. 
Onset of action in 3-5 min. Average 
duration of action up to 30 min. Mean 
recovery time about 90-150 min.
- intravenous route of administration: 1-2 
mg/kg slowly over 1 min (to prevent 
transient respiratory apnoea and enhanced 
pressor response). Onset of action in 30-45 
sec. Duration is about 7-15 min. Repeating 
doses of 0.25-0.5 mg/kg can be given every 
10 min as required or 30-90 µg/kg/min. 
Mean recovery time is approximately 60-
90 min. 
- pre-emptive analgesia: 0.15-0.25 mg/kg IV
Adjunctive medications
It still controversial because of controlled clinical 
studies has not been performed. 
Anticholinergic drugs (e.g., atropine) are often 
administered with ketamine to prevent the 
hypersalivation (antisialagogue effect) that occurs 
in some patients. Dose of atropine is 0.02 mg/kg 
with only needs to be given with the initial dose of 
ketamine. Benzodiazepines (diazepam, lorazepam, 
midazolam) are widely used along with ketamine in 
order to reduce the incidence of the emergence 
phenomenon, but it increases respiratory depression 











emergence phenomenon (disorientation, 
sensory and perceptual illusions, vivid 
dreams, euphoria, excitement and fear). 
This phenomenon occurs at up to 30% 
patients. The presumed cause is that R (-)-
enantiomer has high affinity for sigma 
62 opioids receptor. Risk factors: age over 10 
years, female sex, rapid IV administration, 
prior personality disorders, excessive noise 
63, 64
or stimulation during recovery.
CONTRAINDICATIONS
Øhypersensitivity
severe cardiovascular disease: unstable 
angina pectoris, decompensated heart 
failure, malignant arterial hypertension
Øprevious psychotic abnormality
intra-ocular pathology: glaucoma, acute 
globe injury
Øhigh predisposition to laryngospasm or 
apnoea: active pulmonary or upper airway 
infection; age less 3 months, procedures 
involving stimulation of posterior pharynx
Øcerebral spinal fluid obstructive states: 
severe head injury, space-occupying 
lesions in CNS, hydrocephalus
Øfull meal within 3-4 hours (increased risk of 
aspiration)
INTERACTIONS
Inhalation anaesthetics: blocks the indirect cardiac 
stimulating of ketamine
Halothane: decreased hepatic clearance of 
ketamine, resulting to prolonged recovery
Benzodiazepines: increases sedative effects
Propofol: “ketofol”, strengthening of sedative and 
 65analgesic properties
Opioids: decreased opioids requirements 
Non-depolarizing muscle relaxants: potentiation of 
neuromuscular blockade.
REFERENCES
1. Jochberger, S., Ismailova, F., Lederer, W. et al. 
Anesthesia and its allied disciplines in the 
developing world: a nationwide survey of the 
Republic of Zambia. Anesth Analg 2008;106 
(3): 942-948. 
Medical Journal of Zambia, Vol. 37, No. 3 (2010)
 
2. Domino, E.F., Corssen, G. Dissociative 
anesthesia: further pharmacological studies and 
first clinical experience with the phencyclidine 
derivative CI-581. Anesth Analg 1966;45:29-
40.
3. Kraus, B., Green, S.M. Sedation and analgesia 
for procedures in children. N Engl J Med 2000; 
342: 938-945.
4. Kruger, A.D. Current aspects of using ketamine 
in  chi ldhood.  Anaes thes io logie  und 
Reanimation 1998; 23 (3): 64-71.
5. White, P.F., Ham, J., Way, W.L. et al. 
Pharmacology of ketamine isomers in surgical 
patients. Anesthesiology 1980; 52: 231. 
6. White, M., de Graaff, P., Renshof, B., ven Kan, 
E., Drolijic, M. Pharmacokinetics of S (+) 
ketamine derived from target-controlled 
infusion. Brit J Anaesth 2006; 96 (3): 330-334.
7. Harrison, N.L., Sear, I.W. Chapter 24: 
Intravenous anesthetics. In: Evers AS, Maze M 
(eds). Anesthetic pharmacology: physiologic 
principles and clinical practice. Elsevier. Inc, 
2004: 407.
8. Reves, J.G., Glass, P.S.A, Lubarsky, D.A., 
McEvoy, M.D. Chapter 10: Intravenous 
nonopioid anesthetics. In: Robert D. Miller. 
th
Miller's Anesthesia (6  edition): Churchill 
Livingstone, 2005: 346. 
9. Clements JA, Nimmo WS. Pharmacokinetics 
and analgesic effect of ketamine in man. Br J 
Anaesth 1981; 53: 27-30.
10. Miyasaka, M., Domino, E. Neural mechanisms 
of ketamine-induced anesthesia. Int J 
Neuropharmacol 1968; 7: 557-573.
11. Idvall, J. Ketamine – a review of clinical 
applications. Anesth Pharm Rev 1995; 3: 82-89. 
12. Orser, B.A., Pennefather PS, MacDonald JF. 
Multiple mechanisms of ketamine blockade on 
N - m e t h y l - D - a s p a r t a t e  r e c e p t o r s .  
Anesthesiology 1997; 86: 903-917.
13. Ohtani, M., kikuchi, H., Kitahata, L.M. et al. 
Effects of ketamine on nociceptive cells in the 
medial medullary reticular formation of the cat. 
Anesthesiology 1979; 51: 414-417. 
14. Vincent, J.P., Cavey, D., Kamenka, J.M. et al. 
Interaction of phenylcyclidines with the 
muscarinic and opiate receptors in the CNS. 
Brain Res 1978; 152: 176.
15. Cromhout, A. Ketamine: its use in the 
emergency department. Emerg Med 2003; 15 
(2): 155-156.
16. Schwartz, M.S., Virden, S and Scott, D.F. 
E f f e c t s  o f  k e t a m i n e  o n  t h e  
electroencephalogram. Anaesthesia 1974; 29: 
135. 
17. Bennett, D.R., Madsen, J.A., Jordan, W.S. et al. 
Ketamine anesthesia in brain-damaged 
epileptics: electroencephalographic and clinical 
observations. Neurology 1973; 23: 449.
18. Artru, A., Katz, R.A. Cerebral blood volume and 
CSF pressure following administration of 
ketamine in dogs: modification by pre- and post-
treatment with hypocapnia or diazepam. J 
Neurosurg  Anesth 1989; 1: 8.
19. Thorsen, T., Gran, L. Ketamine/diazepam 
infusion anesthesia with special attention to the 
effect on cerebrospinal fluid pressure and 
arterial blood pressure. Acta Anaesthesiol Scand 
1980; 24: 1-4. 
20. Pfenninger, E. Neuroprotection by ketamine at 
the cellular level. Anaesthetist 1997; 46: S47-
54. 
21. Marco, F.W., Goodrich, J.E. and Dominick, 
M.A. Ketamine prevents ischemic neuronal 
injury. Brain Res 1988; 452: 329.
22. Reeker, W., Werner, C., Mollenberg, O. et al. 
High-dose S (+)-ketamine improves 
neurological outcome following incomplete 
cerebral ischemia in rats. Can J Anaesth 2000; 
47: 572-578. 
23. Albin, M.S. et al. Ketamine hydrochloride fails 
to protect against acute global hypoxia. Anesth. 
Rev 1988; 15: 80.
24. Slogoff, S., Allen, G.W. The role of 
baroreceptors in the cardiovascular response to 
ketamine. Anesth Analg 1974; 53: 704-707.
25. Zsigmond, E., Kothary, S., Matsuki, A. 
Diazepam for prevention of the rise in plasma 
catecholamines caused by ketamine. Clin 
Pharmacol Ther 1974; 15: 223. 
26. Salt, P.J., Barnes, P.K., Beswick, F.J. Inhibition 
of neuronal and extraneuronal uptake of 
noradrenaline by ketamine in the isolated 
perfused rat heart. Br J Anaesth 1979; 51: 835-
838.
27. Johnstone, M. The cardiovascular effects of 
ketamine in man. Anaesthesia 1976; 31: 873.
28. Lippmann, M., Appel, P.L., Mok, M.S. et al. 
Sequential cardiorespiratory patterns of 
anesthetic induction with ketamine in critically 
ill patients. J Crit Care Med 1983; 11: 731-734.  
29. Folts, J.D., Afonso S, Rowe GG et al. Systemic 
and coronary hemodynamic effects of ketamine 
in intact anaesthetized and unanaesthetized 
dogs. Br J Anaesth 1975; 47: 686.
190
Medical Journal of Zambia, Vol. 37, No. 3 (2010)
191
30. Hickey, P.R., Hansen, D.D., Cramolini, G.M. et 
al. Pulmonary and systemic hemodynamic 
responses to ketamine in infants with normal 
and elevated pulmonary vascular resistance. 
Anesthesiology 1985; 62: 287-293. 
31. Sato, T. Ketamine relaxes airway smooth 
muscle contracted by endothelin. Anesth Analg 
1997; 84: 900-906. 
32. Nagdeve, N.G., Yaddanapudi, S., Pandav, S.S. 
The effect of different doses of ketamine on 
intraocular pressure in anesthetized children. J 
Pediatr Ophthalmol Strabismus 2006; 43 (4): 
219-223.  
33. Correll, G.E., Futter, G.E. Two cases studies of 
patients with major depressive disorder given 
low-dose (subanesthetic) ketamine infusions. 
Pain Med 2006; 7 (1): 92-95.
34. Khamsi, R. Ketamine relieves depression within 
hours. New Scientist August 08, 2006.
35. Liebrenz, M., Borgeat, A. et al. Intravenous 
ketamine therapy in patients with a treatment-
resistant major depression. Swiss Med. Wkly 
2007; Apr. 21; 137 (15-16): 234-236. 
36. Kudoh, A., Takahira, Y. et al. Small-dose 
ketamine improves the postoperative state of 
depressed patients. Anesth  Analg 2002; 95 (1): 
114-118. 
37. Krupitsky, E.M., Grinenko, A.Y. Ketamine 
psychedelic therapy (KPT): a review of the 
results of ten years of research. J Psychoactive 
Drugs 1997; 29 (2): 165-183.     
38. Krupitsky, E.M., Burakov, A.M., Dunaevsky IV 
et al. Single versus repeated sessions of 
ketamine-assisted psychotherapy for people 
with heroin dependence. J Psychoactive Drugs 
2007; 39 (1): 13-19. 
39.
40. Chapman, V., Dickenson, A.H. The combination 
of NMDA antagonism and morphine produces 
profound antinociception in the rat dorsal horn. 
Brain Res 1992; 573: 321-323. 
41. Kafali, H., Aldemir, B., Kaygusuz, K. et al. 
Small-dose ketamine decreases postoperative 
morphine requirements. Eur J Anaesthesiol 
2004; 21 (11): 916-917. 
42. Schmid, R.L., Sandler, A.N., Katz, J. Use and 
efficacy of low-dose ketamine in the 
management of acute postoperative pain: a 
review of current techniques and outcomes. 
Pain 1999; 82: 111-125.
43. Dahl, J.B., Moiniche, S. Pre-emptive analgesia. 
Brit Med Bulletin 2004; 71: 13-27.  
http://www.nzdf.org.nz/ketamine
44. Campbell-Fleming JM, Williams A. The use of 
ketamine as adjuvant therapy to control severe 
pain. Clin J Oncol Nurs 2008; 12 (1): 102-107.
45. Bartoc, C., Frumento, R.J., Jalbout, M. et al. 
 
46. Roytblat, L., Roy-Shapira A, Greemberg SL et 
al: Preoperative low-dose ketamine reduces 
serum IL-6 response after abdominal 
hysterectomy. Pain Clin 1996; 9: 327-334.
47. Roytblat, L., Talmor, D., Rachinsky, M. et al: 
Ketamine attenuates the interleukin-6 response 
after cardiopulmonary bypass. Anesth Analg 
1998; 87: 266-271. 
48. Kingston, H.G., Bretherton KW, Holloway AM 
et al. A comparison between ketamine and 
d i a z e p a m  a s  i n d u c t i o n  a g e n t s  f o r  
pericardiectomy. Anaesth Intensive Care 1978; 
6: 66-70. 
49. Van der Linden, P., Gilbart, E., Engelman, E. et 
al. Comparison of halothane, isoflurane, 
alfentanil and ketamine in experimental septic 
shock. Anesth Analg 1990; 70: 608-617. 
50. Taniguchi, T., Shibata, K., Yamamoto, K. 
Ketamine inhibits endotoxin-induced shock in 
rats. Anesthesiology 2001; 95: 928-932.
51. Burburan, S.M., Xisto DG, Rocco PRM. 
Anaesthetic management in asthma. Minerva 
Anesthesiol 2007; 73: 357-365.
52. Corssen, G., Guitierrez, J., Reves, J.G. et al. 
Ketamine in the anesthetic management of 
asthmatic patients. Anesth Analg 1972; 51: 588-
596. 
53. Wanna, H.T., Gergis SD. Procaine, lidocaine, 
and ketamine inhibit histamine-induced 
contracture of guinea pig tracheal muscle in 
vitro. Anesth Analg 1978; 57: 25-27.  
54. L'Hommedieu, C.S. The use of ketamine for the 
emergency intubation of patients with status 
asthmaticus. Ann Emerg Med 1987; 16: 568-
571. 
55. Howton, J.C., Rose, J., Duffy, S., Zoltanski, T., 
Levitt MA. Randomized, double-blind, 
placebo-controlled trial of intravenous 
ketamine in acute asthma. Ann Emerg Med 
1996; 27:170-175. 
56. Yang, C.Y., Wong, C.S., Chang, J.Y. et al. 
Intrathecal ketamine reduces morphine 
A 
randomized, double-blind, placebo-controlled 
study assessing the anti-inflammatory effects of 
ketamine in cardiac surgical patients. J 
Cardiothorac Vasc Anesth 2006; 20 (2): 217-
222.
Medical Journal of Zambia, Vol. 37, No. 3 (2010)
192
requirements in patients with terminal cancer 
pain. Can J Anaesth 1996; 43: 379-383. 
57. Unlugenс, H., Ozalevi, M., Gunes, Y. et al. A 
double-blind comparison of intrathecal S (+)-
ketamine and fentanyl combined with 
bupivacaine 0.5% for Caesarean delivery. Eur J 
Anaesthesiol 2006; 7: 1-7. 
58. Weber, F., Wulf, H. Caudal bupivacaine and S 
(+)-ketamine for postoperative analgesia in 
children. Pediatr Anaesth 2003; 13: 244-248.
59. Malinovsky, J.M., Lepage, J.Y., Cozian, A. et al. 
Is ketamine or its preservative responsible for 
neurotoxicity in the rabbit? Anesthesiology 
1993; 78: 109-115. 
60. Gutstein, H.B., Johnson, K.L., Heard MB et al. 
Oral ketamine preanesthetic medication in 
children. Anesthesiology 1992; 76: 28-33. 
61. Tobias, J.D., Phipps S, Smith B et al. Oral 
ketamine premedication to alleviate  the distress 
of invasive procedures in pediatric oncology 
patients. Pediatrics 1992; 90: 537-541.  
62. Harrison, N.L., Sear, I.W. Chapter 24: 
Intravenous anesthetics. In: Evers AS, Maze M 
(eds). Anesthetic pharmacology: physiologic 
principles and clinical practice. Elsevier. Inc, 
2004: 408.
63. Garfield, J.M., Garfield, F.B., Stone, J.G. et al. A 
comparison of psychologic responses to 
ketamine and thiopental-nitrous oxide-
halothane anesthesia. Anesthesiology 1972; 36: 
329-338.  
64. Sussman, D.R. A comparative evaluation of 
ketamine anesthesia in children and adults. 
Anesthesiology 1974; 40: 459-464.  
65. Willman, E.V., Andolfatto, G. A prospective 
evaluation of “ketofol” (ketamine/propofol 
combination) for procedural sedation and 
analgesia in the emergency department. Ann 
Emerg Med 2007; 49 (1): 23-30. 
